Feola M.,Cardiovascular Rehabilitation Heart Failure Unit |
Garrone O.,Nuclear Medicine Service |
Occelli M.,Nuclear Medicine Service |
Francini A.,Nuclear Medicine Service |
And 4 more authors.
International Journal of Cardiology | Year: 2011
Anthracyclines are among the most active drugs in breast cancer patients. We planned to evaluate the early and 2-year modification of left ventricular ejection fraction (LVEF) and the effects of chemotherapy on troponin I and neurohormonal assessment. Methods: Patients with early breast cancer surgically treated and eligible to adjuvant chemotherapy were enrolled. All patients underwent clinical assessment, radionuclide ventriculography, troponin I and brain natriuretic peptide (BNP) measurements at baseline and one-month (T1), one year (T2) and 2-year (T3) after chemotherapy. Reductions of LVEF ≥ 10% or an overt heart failure were considered cardiovascular events. Results: 53 patients, 52 females and 1 male, age 55.3 years were included and followed at T3. A significant reduction of LVEF was observed (from 62 ± 5.5% to 59.3 ± 8.6%, p = 0.04) at T3; BNP increased (from 33.4 ± 41.5 pg/ml to 62.7 ± 94.7 pg/ml, p = 0.005) at T1. Troponin I augmented at T1 (from 0.006 ± 0.01 ng/ml to 0.05 ± 0.04 ng/ml, p = 0.0001) but normalized at T2 (0.005 ± 0.08 ng/ml; p = 0.9). Only baseline BNP was nearly to be significantly correlated with T3 LVEF (p = 0.07 HR 0.96-1) at multivariate analysis. In 13/53 patients (32.1%) LVEF showed ≥ 10% reduction at T3 (group A); in 40/53 patients (67.9%) LVEF was unchanged (group B). Patients in group A demonstrated higher baseline plasma BNP (p = 0.02) and lower haemoglobin concentration (p = 0.007) compared to patients in group B. Conclusions: LVEF and BNP modified early after anthracycline chemotherapy and LVEF did not recover at T3. In patients who developed left ventricular systolic dysfunction, a subclinical activation of neurohormonal profile was observed. © 2009 Elsevier Ireland Ltd.
News Article | September 19, 2016
Grand Forks, North Dakota, Sept. 19, 2016 (GLOBE NEWSWIRE) -- The Energy & Environmental Research Center (EERC), a worldwide leader in the development of solutions to energy and environmental challenges, announced it is working with the Department of Energy (DOE) National Energy Technology Laboratory (NETL) and Hitachi High Technologies America, Inc., to improve assessment methods for estimating the storage capacity of carbon dioxide (CO ) in tight shale formations, such as the Bakken. The project is funded by NETL with cost share provided by Hitachi. “Although significant progress has been made globally to investigate the suitability of subsurface geologic sinks for CO storage, there is a lack of detailed geologic and petrophysical data needed to develop better techniques for assessing CO storage resources within unconventional formations,” said Bethany Kurz, EERC Principal Hydrogeologist, Laboratory Analysis Group Lead. EERC researchers will develop advanced analytical techniques to better understand and quantify the distribution of clay minerals, organics, pore networks, and fractures in representative shale and tight rock samples. The analytical methods will be developed using imagery collected from a field emission scanning electron microscope (FESEM), which provides the high-resolution images necessary for detection and characterization of the formation. Project participant and cosponsor Hitachi High Technologies America, Inc., will work alongside the EERC to improve the data processing and image analysis within the FESEM software. “We are so pleased to be working with Hitachi on this project,” continued Kurz. “One of the key challenges in estimating CO storage capacity in organic-rich shale is that the analytical equipment and methods used to evaluate conventional reservoirs are limited when applied to shales that require analysis at such a small scale. Hitatchi’s technology and image analysis expertise will greatly improve our ability to efficiently identify and quantify key features of interest within the shales and other tight rocks.” “Working with the EERC offers an exciting opportunity to utilize and develop Hitachi electron imaging technologies for the advanced characterization of unconventional reservoirs,” said Chad Ostrander, VP/GM of Hitachi High-Technologies Canada, Inc. “The potential technology improvements offer both environmental and economic benefits on a global scale, and Hitachi is pleased to be part of this initiative.” The effects of CO exposure on shale samples will also be analyzed by scientists at NETL’s CT Scanning Lab in Morgantown, West Virginia. NETL staff will also be involved to ensure that the project supports the goals of the Carbon Storage Program, which aims to improve the ability to predict CO storage capacity in geologic formations to within ±30%. The EERC is a world leader in developing cleaner, more efficient energy and environmental technologies to protect and clean our air, water, and soil. The EERC, a high-tech, nonprofit division of the University of North Dakota, operates like a business and pursues an entrepreneurial, market-driven approach in order to successfully demonstrate and commercialize innovative technologies. Since 1987, the EERC has had over 1340 clients in 52 countries. Hitachi High Technologies America, Inc. ("HTA") is a privately-owned global affiliate company that operates within the Hitachi Group Companies. HTA sells and services semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products as well as industrial equipment, electronic devices, and electronic and industrial materials.
PubMed | Nuclear Medicine, Radiology, Cardiology, Clinical Trial Scientific Direction and 3 more.
Type: Review | Journal: Translational oncology | Year: 2016
Abiraterone acetate is an effective drug for castration-resistant prostate cancer, but cardiac serious adverse events (SAEs) may occur. We studied their association with N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T (TnT) during abiraterone therapy.In a single institution, 17 patients were treated with abiraterone acetate 1 g daily with concomitant prednisone and then switched to dexametasone plus canrenone. Blood samples for PSA, NT-proBNP, and TnT were obtained at baseline and after 1, 3, and 6 months.Five patients (29.4%) experienced G3 to 4 cardiac SAEs after a median of 13 weeks (range, 9-32), including pulmonary edema, heart failure, acute coronary syndrome, sinus bradycardia with syncope, and pulmonary edema. At baseline, 4 weeks, and 3 months, median NT-proBNP and TnT levels were higher in patients with subsequent cardiac SAEs (P= .03 and P= .04 for NT-proBNP and TnT at 3 months, respectively). After switching to dexametasone and introducing canrenone, no additional cardiac SAEs were noted. Overall response rate was 67%.Our study suggests a higher than expected risk of cardiac SAEs during abiraterone treatment which may well be due to the small sample size and the unrestricted entry criteria. However, baseline and frequent NT-proBNP and TnT monitoring predicted a higher risk for cardiac SAE. Larger studies should confirm our findings.
Grossini E.,University of Piemonte Orientale |
Molinari C.,University of Piemonte Orientale |
Pollesello P.,Orion Pharma |
Bellomo G.,Laboratory Analysis |
And 6 more authors.
Journal of Pharmacology and Experimental Therapeutics | Year: 2012
Ischemia/reperfusion (I/R) injury is an important cause of acute renal failure because of oxidative, inflammatory, and apoptotic mechanisms. The aim of the present study was to examine any possible protective effects of levosimendan in an in vivo pig model of renal I/R injury. In 40 anesthetized pigs (eight groups of five pigs each), I/R was induced by clamping-reopening the left renal artery. During ischemia, in three groups of pigs, levosimendan and the multiorgan preservation solution Custodiol, alone or in combination with levosimendan, were infused in the renal artery. In two other groups of animals, levosimendan in combination with Custodiol was administered after the intrarenal nitric-oxide (NO) synthase blocker Nω-nitro-L-arginine methyl ester (L-NAME) or the mitochondrial ATP-sensitive K+channel (K ATP channel) inhibitor 5-hydroxydecanoate (5-HD). In the other animals, saline, L-NAME, or 5-HD were administered alone. Throughout the experiments, urinary N-acetyl-β-glucosaminidase (NAG) release was measured, and renal function was assessed. Moreover, renal biopsy samples were taken for the detection of apoptosis and tissue peroxidation. In pigs treated with levosimendan or the combination of levosimendan and Custodiol, NAG, peroxidation, and apoptotic markers were lower than in animals treated with Custodiol alone. In addition, renal function was better preserved, and cell survival and antioxidant systems were more activated. All beneficial effects were prevented by L-NAME and 5-HD. In conclusion, levosimendan alone or in combination with Custodiol exerted better protection against renal I/R injuries than Custodiol alone through antioxidant, antiapoptotic, and prosurvival actions depending on mitochondrial KATP channels and NO-related mechanisms. Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics.
PubMed | Clinical Immunology, Haematology and Laboratory Analysis
Type: Journal Article | Journal: International journal of laboratory hematology | Year: 2016
We evaluated analytical and clinical performances of IgG and IgM anticardiolipin (aCL) antibodies and anti-2-glycoprotein I (a-2GpI) antibodies and upper limit reference ranges (99th percentiles) in comparison with manufacturers cutoff values with different commercial methods.We assayed aCL and a-2GpI in serum samples from 30 healthy individuals, 77 patients with antiphospholipid syndrome (APS) diagnosed according to the Sydney criteria, 51 patients with autoimmune diseases, eight patients with previous thrombotic events, six patients with other diseases, and 18 patients with infectious diseases, using ELISA Inova Diagnostics; EliA Phadia Laboratory Systems; CliA Zenit-RA; and CliA Bio-Flash.Anticardiolipin and a-2GpI IgG and IgM immunoassays showed good analytic performances with both 99th percentile and manufacturers cutoff reference values. Our results showed fair to moderate agreement among assays. In-house cutoff values gave significantly better performances only for a-2GpI IgG with all the immunoassays analyzed with the exception of Inova CliA Bio-Flash where we obtained the same performances with in-house and manufacturers cutoffs.By guidelines, all laboratories are strongly advised to validate/verify the manufacturers cutoff values. We recommend establishing low-positive, medium-/high-positive, and high-positive CliA IgG aCL and a-2GpI ranges in order to help clinicians in the diagnosis and treatment of APS.
Ganzetti G.,Marche Polytechnic University |
Simonetti O.,Marche Polytechnic University |
Campanati A.,Marche Polytechnic University |
Giuliodori K.,Marche Polytechnic University |
And 4 more authors.
Acta Dermatovenerologica Croatica | Year: 2015
Osteopontin (OPN) is a multifunctional glycophosphoprotein secreted by many cell types, including osteoblasts, lymphocites, macrophages, epithelial cells, and vascular smooth muscle cells. It has been implicated in many physiological and pathological processes, such as cell-mediated immunity, inflammation, cell survival, and tumor invasion and metastasis. Osteopontin has multiple emerging roles in cutaneous biology and pathology and OPN involvement has been emphasized in Th1-mediated diseases such as psoriasis. Alopecia areata (AA) is a form of non-scarring hair loss affecting anagen stage hair follicles with a multifactorial autoimmune pathogenesis characterized by a prevalent Th1 cytokine profile. Given the role of osteopontin in Th1-mediated inflammation, we have postulated that OPN may be involved in AA pathogenesis. The aim of our study was to investigate plasma OPN level in alopecia areata before and after DPCP treatment. Our results showed that OPN plasma levels in patients with alopecia areata were higher than in healthy controls, but patients achieving complete recovery after DPCP treatment did not show a statistically significant reduction of OPN plasma levels. © 2015, Croatian Dermatovenerological Society. All right reserved.